Lymphomatoid papulosis in a patient with recurrent Hodgkin's lymphoma: a clinical case
pdf (Русский)

Keywords

lymphomatoid papulosis
Hodgkin's lymphoma
relapse of lymphoma
recurrent lymphoma

How to Cite

Kramynin, L., Motalkina , M., Filatova, L., Zyuzgin, I., & Artemyeva, A. (2023). Lymphomatoid papulosis in a patient with recurrent Hodgkin’s lymphoma: a clinical case. Voprosy Onkologii, 69(3), 549–554. https://doi.org/10.37469/0507-3758-2023-69-3-549-554

Abstract

Lymphomatoid papulosis is an extremely rare skin disease occurring with a frequency of 1.2 – 1.9 cases per 1 million people per year. It has a very favorable prognosis: the 5-year survival rate is about 100%. However, such patients have an increased risk of developing secondary tumors compared to the general population. Mycosis Fungoides and cutaneous or systemic anaplastic large cell lymphoma are most often associated with lymphomatoid papulosis. Cases of lymphomatoid papulosis and Hodgkin's lymphoma in one patient are isolated, which makes them unique and requires a multidisciplinary and individualized approach to treatment and monitoring. This article presents a clinical case of a patient with lymphomatoid papulosis, against the background of which classical Hodgkin's lymphoma recurred twice.

https://doi.org/10.37469/0507-3758-2023-69-3-549-554
pdf (Русский)

References

Assaf C, Gellrich S, Steinhoff M, et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges. 2007;5(8):6628. doi:10.1111/j.1610-0387.2007.06337.x.

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):17201748. doi:10.1038/s41375-022-01620-2.

Willemze R. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification. Leuk Lymphoma. 2003;44 Suppl 3:S4954. doi:10.1080/10428190310001623766.

Namba H, Hamada T, Iwatsuki K. Human T-cell leukemia virus type 1-positive lymphomatoid papulosis. Eur J Dermatol. 2016;26(2):1945. doi:10.1684/ejd.2015.2707.

Kadin ME, Levi E, Kempf W. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann N Y Acad Sci. 2001;941:5968. doi:10.1111/j.1749-6632.2001.tb03711.x.

Wagner G, Rose C, Klapper Wet al. Lymphomatoid papulosis. J Dtsch Dermatol Ges. 2020;18(3):199205. doi:10.1111/ddg.14041.

Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):402435. doi:10.1182/blood-2011-05-351346.

Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):365361.

Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. 1992;126(6):596602. doi:10.1111/j.1365-2133.1992.tb00106.x.

Olsen EA, Delzell E, Jegasothy BV. Second malignancies in cutaneous T cell lymphoma. J Am Acad Dermatol. 1984;10(2Pt1):197204. doi:10.1016/s0190-9622(84)70023-5.

Melchers RC, Willemze R, Bekkenk MW, et al. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 2020;34(2):260266. doi:10.1111/jdv.16065.

Nowicka D, Mertowska P, Mertowski S, et al. Etiopathogenesis, diagnosis, and treatment strategies for lymphomatoid papulosis with particular emphasis on the role of the immune system. Cells. 2022;11(22):3697. doi:10.3390/cells11223697.

Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer. 1999;86(7):12405.

Gan EY, Tang MB, Tan SH. Lymphomatoid papulosis: is a second lymphoma commoner among East Asians? Clin Exp Dermatol. 2012;37(2):11821. doi:10.1111/j.1365-2230.2011.04124.x.

Kunishige JH, McDonald H, Alvarez G, et al. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009;34(5):57681. doi:10.1111/j.1365-2230.2008.03024.x.

De Souza A, el-Azhary RA, Camilleri MJ, et al. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol. 2012;66(6):92837. doi:10.1016/j.jaad.2011.07.012.

Wieser I, Oh CW, Talpur R, et al. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016;74(1):5967. doi:10.1016/j.jaad.2015.09.013.

Cordel N, Tressières B, D'Incan M, et al. French study group on cutaneous lymphoma. frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis. Oncologist. 2016;21(1):7683. doi:10.1634/theoncologist.2015-0242.

AbuHilal M, Walsh S, Shear N. Associated hematolymphoid malignancies in patients with lymphomatoid papulosis: a canadian retrospective study. J Cutan Med Surg. 2017;21(6):507512. doi:10.1177/1203475417716366.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2023